Top-News
Biotechnologie USA

CytomX Therapeutics Inc Aktie

Aktie
WKN:  A14158 ISIN:  US23284F1057 US-Symbol:  CTMX
0,80 $
+0,0432 $
+5,71%
0,7060 € 16:59:09 Uhr
Depot/Watchlist
Aktienanzahl *
78,26 Mio.
Marktkapitalisierung *
51,41 Mio. €
Streubesitz
40,54%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 31.01.2025

CytomX Therapeutics Inc News

01.02.25 - Boersia.de
CytomX Therapeutics Aktie: Deutlicher Rückschritt?
Der Biotechnologie-​Konzern CytomX Therapeutics verzeichnet eine deutliche Abwärtsbewegung an der Börse. Der Aktienkurs des Unternehmens fiel zum 1. Februar 2025 auf ...
26.01.25 - Boersia.de
CytomX Therapeutics Aktie: Zukunftstrends im Blick
Die Aktie des Biotech-​Unternehmens CytomX Therapeutics zeigt aktuell eine leichte Erholung im Markt. Der Kurs stieg am 25. Januar 2025 um 2,35 Prozent auf 0,87 EUR, was eine ...
02.11.24 - Boersia.de
CytomX Therapeutics Aktie: Was bedeutet das für Anleger?
Die CytomX Therapeutics Aktie verzeichnete am 2. November 2024 einen leichten Rückgang von 1,04% auf 0,95 EUR. Trotz dieses kurzfristigen Rücksetzers konnte das ...
17.01.23 - DerFinanzinvestor
Übernahme und Absturz - CytomX, Defence Therapeutics, Moderna, Novavax
Während Finanzminister Lindner wegen einer erheblichen Milliardenlücke im Bundeshaushalt durch massiv gestiegene Zinszahlungen den Ministerien nun erst ...
06.01.23 - PR Newswire
Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions?
Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions? PR Newswire
05.01.23 - PR Newswire
Thinking about buying stock in Novocure, Zai Lab, Kala Pharmaceuticals, Orchard Therapeutics, or CytomX Therapeutics?
Thinking about buying stock in Novocure, Zai Lab, Kala Pharmaceuticals, Orchard Therapeutics, or CytomX Therapeutics? PR Newswire
17.11.22 - PR Newswire
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer PR Newswire
26.09.22 - PR Newswire
Thinking about buying stock in iSpecimen, Leslie's, Las Vegas Sands, Atlas Corp, or CytomX Therapeutics?
Thinking about buying stock in iSpecimen, Leslie's, Las Vegas Sands, Atlas Corp, or CytomX Therapeutics? PR Newswire
23.03.21 - PR Newswire
Thinking about buying stock in Ion Geophysical, OncoCyte, electroCore, CytomX Therapeutics, or Catalyst Biosciences?
Thinking about buying stock in Ion Geophysical, OncoCyte, electroCore, CytomX Therapeutics, or Catalyst Biosciences? PR Newswire
10.07.20 - PR Newswire
ROSEN, A LONGSTANDING AND TOP RANKED FIRM, Reminds CytomX Therapeutics, Inc. Investors of Important Deadline in Securities Class Action - CTMX
ROSEN, A LONGSTANDING AND TOP RANKED FIRM, Reminds CytomX Therapeutics, Inc. Investors of Important Deadline in Securities Class Action - CTMX PR Newswire
07.07.20 - PR Newswire
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds CytomX Therapeutics, Inc. Investors of Important Deadline in Securities Class Action - CTMX
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds CytomX Therapeutics, Inc. Investors of Important Deadline in Securities Class Action - CTMX PR Newswire
27.06.20 - PR Newswire
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm PR Newswire
22.06.20 - PR Newswire
ROSEN, A LEADING NATIONAL FIRM, Reminds CytomX Therapeutics, Inc. Investors of Important July 20 Deadline in Securities Class Action - CTMX
ROSEN, A LEADING NATIONAL FIRM, Reminds CytomX Therapeutics, Inc. Investors of Important July 20 Deadline in Securities Class Action - CTMX PR Newswire
04.06.20 - PR Newswire
Moore Kuehn, PLLC Encourages Investors of CLNY, SRNE, and CTMX to Contact Law Firm
Moore Kuehn, PLLC Encourages Investors of CLNY, SRNE, and CTMX to Contact Law Firm PR Newswire
22.05.20 - PR Newswire
CYTOMX LOSS ALERT, ROSEN, A TOP RANKED INVESTOR FIRM, Announces Filing of Securities Class Action Lawsuit Against CytomX Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CTMX
CYTOMX LOSS ALERT, ROSEN, A TOP RANKED INVESTOR FIRM, Announces Filing of Securities Class Action Lawsuit Against CytomX Therapeutics, Inc.; Encourages Investors ...
22.05.20 - PR Newswire
CTMX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CytomX Therapeutics, Inc. and Encourages Investors to Contact the Firm
CTMX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CytomX Therapeutics, Inc. and Encourages Investors to Contact the Firm PR ...
03.10.17 - PR Newswire
Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology
Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-​Oncology Companies to Jointly Develop T-Cell Engaging Bispecific Probody PR Newswire
21.09.17 - PR Newswire
UNITY Biotechnology Appoints Additional Biotech Industry Veterans to Executive Team
UNITY Biotechnology Appoints Additional Biotech Industry Veterans to Executive Team PR Newswire
21.04.16 - PR Newswire
AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates
AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates - Companies to Jointly Develop and Commercialize Probody Drug Conjugates Directed Against ...

Newssuche

Videos

newspaper
30.04.25 +13,48%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »